Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9
Recently we showed that delta radiomics features (DRF) from daily CT-guided chemoradiation therapy (CRT) is associated with early prediction of treatment response for pancreatic cancer.CA19-9 is a widely used clinical biomarker for pancreatic cancer.The purpose of this work is to investigate if the predictive power of such biomarkers (DRF or CA19-9